As alumni of the DayOne Accelerator Program, we were invited to present alongside promising and influential start-up founders, executives from the pharmaceutical industry, investors, and ecosystem players.
We have not only demonstrated our scientific excellence, but also our ability to operate commercially successfully in order to give patients better access to our innovative, AI-based test for diagnosing coronary heart disease, which offers similar accuracy to imaging techniques but at a significantly lower cost.
